585543-15-3 Usage
Description
Losmapimod (GW856553X) is a dual inhibitor of p38α and p38β MAPK with high selectivity and potency, characterized by Kis values of 0.0079 and 0.025 μM, respectively, in cell-free assays. It demonstrates inhibitory effects on LPS-induced TNF-α production in rat and human peripheral blood mononuclear cells (PBMCs) and has shown to decrease disease severity in a mouse model of collagen-induced arthritis. Additionally, it has beneficial effects on survival, blood pressure, and plasma lipid levels in spontaneously hypertensive stroke-prone rats.
Uses
Used in Pharmaceutical Industry:
Losmapimod (GW856553X) is used as a selective, potent, and orally active p38 MAPK inhibitor for the treatment of various inflammatory and autoimmune diseases. Its ability to inhibit p38α and p38β MAPK makes it a promising candidate for conditions where these kinases play a significant role in disease pathology.
Used in Inflammatory Disease Treatment:
Losmapimod (GW856553X) is used as an anti-inflammatory agent for reducing the severity of diseases like collagen-induced arthritis. Its inhibitory action on p38 MAPK, a key mediator in the inflammatory response, contributes to the amelioration of disease symptoms and progression.
Used in Cardiovascular Disease Management:
In the context of cardiovascular diseases, Losmapimod (GW856553X) is used to improve survival, normalize blood pressure, and reduce the levels of plasma HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet. This suggests its potential application in managing hypertension and related cardiovascular complications.
Used in Research and Development:
Losmapimod (GW856553X) serves as a valuable research tool for studying the role of p38 MAPK in various cellular processes and disease mechanisms. Its high selectivity and potency make it an ideal compound for investigating the therapeutic potential of p38 MAPK inhibition in preclinical models.
references
[1]. willette rn, eybye me, olzinski ar, et al. differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. j pharmacol exp ther, 2009, 330(3): 964-970. [2]. cheriyan j, webb aj, sarov-blat l, et al. inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. circulation., 2011, 123(5): 515-523. [3]. lomas da, lipson da, miller be, et al. an oral inhibitor of p38 map kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. j clin pharmacol, 2012, 52(3): 416-424.
Check Digit Verification of cas no
The CAS Registry Mumber 585543-15-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,5,5,4 and 3 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 585543-15:
(8*5)+(7*8)+(6*5)+(5*5)+(4*4)+(3*3)+(2*1)+(1*5)=183
183 % 10 = 3
So 585543-15-3 is a valid CAS Registry Number.
